4.6 Article

Benefit of early discharge among patients with low-risk pulmonary embolism

期刊

PLOS ONE
卷 12, 期 10, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0185022

关键词

-

资金

  1. Janssen Scientific Affairs, LLC

向作者/读者索取更多资源

Clinical guidelines recommend early discharge of patients with low-risk pulmonary embolism (LRPE). This study measured the overall impact of early discharge of LRPE patients on clinical outcomes and costs in the Veterans Health Administration population. Adult patients with >= 1 inpatient diagnosis for pulmonary embolism (PE) (index date) between 10/2011-06/2015, continuous enrollment for >= 12 months pre-and 3 months post-index date were included. PE risk stratification was performed using the simplified Pulmonary Embolism Stratification Index. Propensity score matching (PSM) was used to compare 90-day adverse PE events (APEs) [recurrent venous thromboembolism, major bleed and death], hospital-acquired complications (HACs), healthcare utilization, and costs among short (<= 2 days) versus long length of stay (LOS). Net clinical benefit was defined as 1 minus the combined rate of APE and HAC. Among 6,746 PE patients, 95.4% were men, 22.0% were African American, and 1,918 had LRPE. Among LRPE patients, only 688 had a short LOS. After 1:1 PSM, there were no differences in APE, but short LOS had fewer HAC (1.5% vs 13.3%, 95% CI: 3.77-19.94) and bacterial pneumonias (5.9% vs 11.7%, 95% CI: 1.24-3.23), resulting in better net clinical benefit (86.9% vs 78.3%, 95% CI: 0.84-0.96). Among long LOS patients, HACs (52) exceeded APEs (14 recurrent DVT, 5 bleeds). Short LOS incurred lower inpatient ($2,164 vs $5,100, 95% CI: $646.8-$5225.0) and total costs ($9,056 vs $12,544, 95% CI: $636.6-$6337.7). LRPE patients with short LOS had better net clinical outcomes at lower costs than matched LRPE patients with long LOS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Health Care Sciences & Services

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review

Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurelie Millier, Olivia Wu

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)

Article Pharmacology & Pharmacy

Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation

Brandon K. Martinez, William L. Baker, Nitesh A. Sood, Thomas J. Bunz, Anna-Katharina Meinecke, Daniel Eriksson, Craig Coleman

PHARMACOTHERAPY (2019)

Article Cardiac & Cardiovascular Systems

Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease

Brandon K. Martinez, William L. Baker, Anna Konopka, Devon Giannelli, Craig I. Coleman, Jeffrey Kluger, Edmond M. Cronin

HEART RHYTHM (2020)

Review Endocrinology & Metabolism

Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria

C. I. Coleman, E. R. Weeda, A. Kharat, B. Bookhart, W. L. Baker

DIABETIC MEDICINE (2020)

Article Emergency Medicine

Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting

Diana M. Sobieraj, Brandon K. Martinez, Benjamin Miao, Mark X. Cicero, Richard A. Kamin, Adrian Hernandez, Craig Coleman, William L. Baker

PREHOSPITAL EMERGENCY CARE (2020)

Article Cardiac & Cardiovascular Systems

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease

Craig Coleman, William L. Baker, Anna-Katharina Meinecke, Daniel Eriksson, Brandon K. Martinez, Thomas J. Bunz, Mark J. Alberts

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)

Article Cardiac & Cardiovascular Systems

Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation

Benjamin Miao, Adrian V. Hernandez, Yuani M. Roman, Mark J. Alberts, Craig I. Coleman, William L. Baker

CLINICAL CARDIOLOGY (2020)

Article Hematology

Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis

Benjamin Miao, Nitesh Sood, Thomas J. Bunz, Craig Coleman

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Article Multidisciplinary Sciences

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurelie Millier, Mondher Toumi, Emilie Clay, Pierre Levy

PLOS ONE (2020)

Article Multidisciplinary Sciences

Physicians' perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey

Tabassum Salam, Amy Duhig, Aarti A. Patel, Ann Cameron, Jennifer Voelker, Brahim Bookhart, Craig I. Coleman

PLOS ONE (2020)

Article Cardiac & Cardiovascular Systems

Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors

Benjamin Miao, Adrian V. Hernandez, Mark J. Alberts, Nicholas Mangiafico, Yuani M. Roman, Craig I. Coleman

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Article Pharmacology & Pharmacy

Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey

Tabassum Salam, Amy Duhig, Aarti A. Patel, Ann Cameron, Jennifer Voelker, Brahim Bookhart, Craig Coleman

CLINICAL THERAPEUTICS (2020)

Article Medicine, General & Internal

Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data

Olivia S. Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J. Bunz, Craig Coleman

CURRENT MEDICAL RESEARCH AND OPINION (2020)

Article Medicine, General & Internal

Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation

Craig Coleman, Stanley Thompson, Veronica Ashton, Michael Palladino, Thomas J. Bunz

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2020)

Article Hematology

Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis

Olivia S. Costa, Stanley Thompson, Veronica Ashton, Michael Palladino, Thomas J. Bunz, Craig Coleman

THROMBOSIS JOURNAL (2020)

暂无数据